IMVT NASDAQ
Immunovant, Inc.
1W: -8.2%
1M: -7.8%
3M: -1.4%
YTD: +1.5%
1Y: +81.8%
3Y: +46.5%
5Y: +68.2%
$26.29
-0.24 (-0.90%)
Weekly Expected Move ±6.8%
$24
$26
$27
$29
$31
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$350.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$5.4B
52W Range13.79-30.16
Volume1,418,325
Avg Volume1,383,404
Beta0.70
Dividend—
Analyst Ratings
Company Info
CEOEric Venker
Employees362
SectorHealthcare
IndustryBiotechnology
IPO Date2019-06-21
Websiteimmunovant.com
320 West 37th Street
New York City, NY 10018
US
New York City, NY 10018
US
917 580 3099
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Latest News
Here are the major earnings before the open Wednesday
Immunovant Q4 2026 Earnings Preview
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
Immunovant (NASDAQ:IMVT) CTO Sells $81,573.48 in Stock
Immunovant (NASDAQ:IMVT) CFO Sells $763,011.20 in Stock
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Susman Robert Graham | S-Sale | 2,502 | $27.17 | 2026-05-01 |
| Girao Tiago | S-Sale | 25,760 | $29.62 | 2026-04-23 |
| Stout Jay S | S-Sale | 2,754 | $29.62 | 2026-04-23 |
| Van Tuyl Christopher | S-Sale | 5,165 | $24.83 | 2026-04-08 |
| Gloria Melanie | S-Sale | 8,722 | $24.83 | 2026-04-08 |